N30 Pharma is a Boulder, Colorado–based biopharmaceutical company focused on developing s-nitrosothiol (SNO)-based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases. Its drug candidates target s-nitrosoglutathione reductase (GSNOR), an enzyme that consumes s-nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool. GSNO and other SNOs are important modulators of inflammation as well as airway and vascular smooth muscle. The company’s lead candidate, N6022, is being advanced toward human testing. A recently completed $10M financing will provide resources to move N6022 into human trials and to support development of additional drugs from its discovery and development platform. In conjunction with the financing, Dr. Howard Furst of Deerfield Management joined N30 Pharma’s board of directors.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

May 2010